Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−5.5 USD
−913.77 M USD
363.71 M USD
207.27 M
About Insmed Incorporated
Sector
Industry
CEO
William H. Lewis
Website
Headquarters
Bridgewater
Founded
1988
ISIN
US4576693075
FIGI
BBG00JVRNS34
Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. The company was founded in 1988 and is headquartered in Bridgewater, NJ.
Related stocks
Insmed (INSM) - Breakout Opportunity 📌 Insmed ( NASDAQ:INSM ) – Breakout Opportunity
Insmed is a clinical-stage biopharmaceutical company focused on serious and rare lung diseases. The stock more than doubled in May 2024 following positive Phase 3 results for its drug Brensocatib. The FDA has granted Priority Review, with a PDUFA
INSM - June 24 Qullamaggie Breakout and Episodic Pivot15 June
Price surfing the 10SMA and making lower highs
There are two large momentum candles bringing price above the consolidation.
It was also one of the rare stocks that was green while the broader market was red
Risk
I know the reason for the new pricing but I am unable to determine if it is so
Insmed Catapults 113% on Positive ASPEN Study ResultsInsmed ( NASDAQ:INSM ), a biotech company, has successfully developed a lung disease drug, brensocatib, which has been shown to significantly reduce the frequency of respiratory symptoms such as chronic cough in a late-stage study. The drug, which is expected to be launched in mid-2025, is expected
Insmed Incorporated (INSM: NASDAQ)Insmed Incorporated (INSM), a biopharmaceutical company, is showing positive developments in its product portfolio. The company reiterated its 2023 guidance, expecting revenue between $295-305 million, with strategic plans to expand the use of its ARIKAYCE product.
Encouraging Phase 2 data for its
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 0JAV is 165.5 USD — it has increased by 1.15% in the past 24 hours. Watch Insmed Incorporated stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange Insmed Incorporated stocks are traded under the ticker 0JAV.
0JAV stock has fallen by −1.58% compared to the previous week, the month change is a 13.27% rise, over the last year Insmed Incorporated has showed a 122.03% increase.
We've gathered analysts' opinions on Insmed Incorporated future price: according to them, 0JAV price has a max estimate of 240.00 USD and a min estimate of 139.00 USD. Watch 0JAV chart and read a more detailed Insmed Incorporated stock forecast: see what analysts think of Insmed Incorporated and suggest that you do with its stocks.
0JAV reached its all-time high on Oct 10, 2025 with the price of 168.0 USD, and its all-time low was 16.5 USD and was reached on Mar 27, 2023. View more price dynamics on 0JAV chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
0JAV stock is 1.80% volatile and has beta coefficient of 0.90. Track Insmed Incorporated stock price on the chart and check out the list of the most volatile stocks — is Insmed Incorporated there?
Today Insmed Incorporated has the market capitalization of 35.04 B, it has increased by 0.53% over the last week.
Yes, you can track Insmed Incorporated financials in yearly and quarterly reports right on TradingView.
Insmed Incorporated is going to release the next earnings report on Oct 30, 2025. Keep track of upcoming events with our Earnings Calendar.
0JAV earnings for the last quarter are −1.70 USD per share, whereas the estimation was −1.30 USD resulting in a −30.84% surprise. The estimated earnings for the next quarter are −1.34 USD per share. See more details about Insmed Incorporated earnings.
Insmed Incorporated revenue for the last quarter amounts to 107.42 M USD, despite the estimated figure of 104.13 M USD. In the next quarter, revenue is expected to reach 115.05 M USD.
0JAV net income for the last quarter is −321.69 M USD, while the quarter before that showed −256.58 M USD of net income which accounts for −25.37% change. Track more Insmed Incorporated financial stats to get the full picture.
No, 0JAV doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Oct 18, 2025, the company has 1.27 K employees. See our rating of the largest employees — is Insmed Incorporated on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Insmed Incorporated EBITDA is −915.32 M USD, and current EBITDA margin is −213.24%. See more stats in Insmed Incorporated financial statements.
Like other stocks, 0JAV shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Insmed Incorporated stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Insmed Incorporated technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Insmed Incorporated stock shows the strong buy signal. See more of Insmed Incorporated technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.